



an Open Access Journal by MDPI

## Emerging Issues in COVID-19: From Diagnosis to Inhibitors

Guest Editors:

**Prof. Dr. Erika Cione**

Department of Pharmacy, Health  
and Nutritional Sciences,  
University of Calabria, 87036  
Rende, Italy

**Dr. Manuela Colosimo**

Department of Virology and  
Microbiology, Pugliese Ciaccio's  
Hospital, 88100 Catanzaro, CZ,  
Italy

Deadline for manuscript  
submissions:

**closed (31 December 2023)**

### Message from the Guest Editors

Dear Colleagues,

The COVID-19 outbreak has been recognized as a global threat to public health. It is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and no effective therapies currently exist against this novel viral agent. Strategies to combat pandemics, such as contact tracking, rapid antigenic testing, and biosensors, are still needed. Genetic research allows for the identification of continuously evolving novel variants of the virus, and epidemiological studies characterize and follow their propagation in various regions of the world in which reinfections are now occurring. This Special Issue aims to describe scientific works with novel antiviral or repositioned drugs that can decrease the severity of the disease but also hopes to focus on the relationship between COVID-19 and clinical outcomes, as well as methods for diagnostic procedures. Authors are welcome to submit articles, communications, opinions, and reviews.

Dr. Erika Cione

Dr. Manuela Colosimo

*Guest Editors*



[mdpi.com/si/121521](https://mdpi.com/si/121521)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI